How many drugs treat Disorder of skin?

Drug Landscape tracks 9 marketed treatments for Disorder of skin (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/disorder-of-skin.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Disorder of skin — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Disorder of skin (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Disorder of skin, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Medrol	methylprednisolone	Generic (originally Upjohn/Pfizer)	Glucocorticoid (corticosteroid)	Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor	1957-10-01
Deltasone	prednisone	Generic (originally Schering)	Corticosteroid [EPC]	Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor	1955-01-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Infuvite Adult	DEXPANTHENOL	Pfizer	dexpanthenol		1953-01-01
prednison	prednison	Wen Zhang		Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor
Methylprednisolon	Methylprednisolon	Leiden University Medical Center		Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor
prednisolon	prednisolon	Hannover Medical School		Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1
Bepanthen	Bepanthen	RWTH Aachen University

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Disorder of skin
Generic (originally Schering) · 2 drugs in Disorder of skin
Generic (originally Upjohn/Pfizer) · 1 drug in Disorder of skin
Hannover Medical School · 1 drug in Disorder of skin
Leiden University Medical Center · 1 drug in Disorder of skin
Pfizer · 1 drug in Disorder of skin
RWTH Aachen University · 1 drug in Disorder of skin
Wen Zhang · 1 drug in Disorder of skin
Generic (originally Merck) · 1 drug in Disorder of skin

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Disorder of skin:

Cite this brief

Drug Landscape (2026). Disorder of skin — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/disorder-of-skin. Accessed 2026-06-10.

Disorder of skin full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing